联康生物科技集团(00690.HK)拟折让增发2.16亿股集资3000万港元
格隆汇7月22日丨联康生物科技集团(00690.HK)宣布,于2019年7月22日,公司拟向兴华企业及中国港澳台侨和平发展基金配售合共2.158亿股,相当于经扩大后股份3.37%,每股0.139港元,较7月22日收市价0.142港元折让约2.11%。
所得款项总额将为约3000万港元,扣除开支后的认购事项所得款项净总额估计约为2990万港元,即每股认购股份的净发行价约0.1385港元。公司计划将所得款项净额用作公司用于治疗骨质疏松及糖尿病的在研产品的研发开支以及一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.